On Sunday, 24 November, Frederik De Smet, our project coordinator, delivered an engaging lecture at KU Leuven’s Health Sciences Campus Gasthuisberg during Science day. He shared his work on immunotherapy and glioblastoma treatments. This was also a great opportunity to show how the GLIOMATCH project leverages immunotherapy and precision medicine to improve outcomes for adults and children with brain tumours.
Visit our photo gallery for more pictures from the event.
GLIOMATCH joined partners of the Understanding (tumour-host interactions) Cluster – an initiative of the EU’s Cancer Mission – in Warsaw in March 2026 to review scientific progress, strengthen collaboration and advance joint work on data management and policy-relevant research.
Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.
On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.
GLIOMATCH celebrates the women researchers across its consortium whose expertise and commitment drive the development of tailored immunotherapies for malignant brain tumours, marking the International Day of Women and Girls in Science 2026.
